Clinical Trial Update: Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating how serum hepcidin responds to iron intake to help differentiate ferroportin disease from dysmetabolic hepatosiderosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diagnosis
• Dysmetabolic Hepatosiderosis
• Ferroportin Disease
• Hemochromatosis Type 4

Snippet

Sponsor: Rennes University Hospital | Conditions: Hemochromatosis, Type 4, Ferroportin Disease | Phase 2 | Status: COMPLETED